bevacizumab-awwb · MVASI

Monoclonal antibody

Also known as ABP 215

Biosimilar of Bevacizumab

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer, Recurrent Glioblastoma, Renal Cell Carcinoma, Cervical Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • Persistent, Recurrent, or Metastatic Cervical Cancer MVASI, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
  • Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer MVASI, in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. MVASI, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy re
Product first approved 2017FDA label
EU
  • Bevacizumab biosimilar (Mvasi): metastatic breast, colorectal, non-squamous NSCLC, renal cell, ovarian and cervical cancers
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Non-Small Cell Lung Cancer
NCT04466917 · Amgen
2021-05-15 – 2022-11-13 · Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
What this study did
Phase 2 (1)
Other / comorbidity
NCT05183984 · ARCAGY/ GINECO GROUP
2022-02-01 – 2032-02-01 · Ovarian Cancer
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT05180422 · Criterium, Inc.
2022-06-15 – 2023-01-31 · Non Small Cell Lung Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT04185883 · Amgen
2019-12-17 – 2027-12-05 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Advanced Metastatic Colorectal Cancer

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bevacizumab-Awwb (MVASI): this drugApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-A
Weak signal(overall)
No reviewed efficacy summary in this indication
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MVASI (bevacizumab-awwb) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-02 · NCT05183984 · CT.gov ↗
What to watch

See the full readout calendar ↗